Sanofi (ADR)

  • Positive News for This Troubled Pharma Player

    By Brandy Betz - August 15, 2013 | Tickers: LLY, MRK, SNY

    Eli Lilly (NYSE: LLY) closed last Tuesday up nearly 3% following positive phase 3 results for cancer drug necitumumab. The company had previously halted a different necitumumab trial for safety issues. This positive bit of news was particularly welcome in the wake of Lilly's late-stage pipeline crashes. And with two blockbuster drugs set to expire in the next year, Eli Lilly needs all the signs of strength it can more »

  • Is This Myelofibrosis Drug a Blockbuster?

    By Kanak Kanti - August 15, 2013 | Tickers: GILD, INCY, SNY

    Bone marrow cancer, also known as Myelofibrosis (MF), is a rare form of cancer that affects both men and women. About 1.5 out of 100,000 people suffer from MF in the U.S. annually, but treatment options are limited. Incyte (NASDAQ: INCY) has developed a small molecule named Jakafi which was approved as first line therapy against MF. Given that this is the only available drug for MF more »

  • 2 Drug Companies to Buy and 1 to Sell

    By Phillip Woolgar - August 15, 2013 | Tickers: ABBV, GILD, SNY

    Drug companies need to consistently develop their product lines in order to fend off competition, much of which is generated from generic drugs. These firms are constantly setting their sights on the next development, so they can develop a patent and help ensure they create an economic moat. That isn't easy, however, as patents expire and these firms need to innovate once again.

    Two of these three firms are more »

  • Which of These Biotechs Can Beat the Bird Flu?

    By Leo Sun - August 15, 2013 | Tickers: BOTA, GILD, GSK, RHHBY, SNY

    The H7N9 bird flu epidemic, which recently claimed its 44th victim in China, has had a widespread impact across the markets, ravaging the airline, hospitality and restaurant sectors in particular. Since the end of March, the Chinese government reported 134 new cases of N7N9, with a single overseas case reported in Taiwan.

    H7N9 is more lethal than its predecessor, H5N1, which claimed more than 360 lives over the past decade more »

  • This Pharma Stock Is Ready to Reach New Heights

    By Kanak Kanti - August 12, 2013 | Tickers: BAYRY.PK, REGN, SNY

    Earlier this year, in May, Regeneron Pharmaceuticals (NASDAQ: REGN) was soaring on news of FDA approval of the Eylea injection. The market valued the company at almost $27 billion at that time. It has come down quite a bit now to nearly $25 billion. Things are now happening again at this counter, with the company preparing to submit an application for approval of Eylea for a new indication, and an more »

  • Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

    By Arturo Cuevas - August 12, 2013 | Tickers: GSK, MRK, SNY

    Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk more »

  • Is This Biotech Slowing?

    By Brandy Betz - August 9, 2013 | Tickers: REGN, RHHBY, SNY

    Regeneron Pharmaceuticals (NASDAQ: REGN) closed Tuesday down over 6% following a second quarter report that missed estimates. A particular cause for concern was the slowed sales growth for macular degeneration drug Eylea. Were investors right to run away?

    If you Google Regeneron’s second quarter right now, you’ll see an odd mix of headlines touting either Eylea’s slowdown or its sales jump. So which is it? It’s more »

  • This Company Is Tackling Multiple Sclerosis Head On

    By Kanak Kanti - August 7, 2013 | Tickers: BIIB, GSK, SNY

    Note: This article has been amended to better reflect Lemtrada's market position.

    Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease. MS has no cure. These drugs have too many side effects due to their lack of target specificity. Another class of drugs, recently being developed, are protein based therapies (monoclonal antibodies or mAbs more »

  • GlaxoSmithKline: Victim or Villain in China?

    By Victor Alagbe - August 7, 2013 | Tickers: AZN, GSK, JNJ, SNY

    The last reported record of something British forcing drugs on the Chinese people was during the opium wars of which we should let sleeping dogs lie. However, it appears that GlaxoSmithKline (NYSE: GSK), a British company has been caught in the act forcing drugs on the Chinese people albeit through prescriptions. The story of GSK's bribery scandal in China is no longer news; but I would like to point more »

  • Sleep War Z: A Written History of the Insomniac War

    By Leo Sun - July 31, 2013 | Tickers: MRK, SNY, VNDA

    It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not require medication. However, 10% to 15% of American adults reportedly suffer from chronic insomnia, which lasts for months at a time. Anxiety and depression are frequent causes of chronic insomnia, and currently available insomnia medications often contain some similar ingredients as more »

  • Out With the Old, In With the New in Treating MS

    By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA

    Hidden beneath all the numbers and metrics in Biogen Idec's (NASDAQ: BIIB) recent earnings report  is a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. 

    What Happened

    On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates more »

  • A Fine Act of balancing by Sanofi

    By Shalini Agrawal - July 27, 2013 | Tickers: LLY, MRK, NVO, SNY


    In the history spanning more than two centuries, Sanofi (NYSE: SNY) has undergone number of major and minor changes to reach the level of integrated healthcare leader as it is today. To achieve this, Sanofi has been quick to spot the value-enhancing growth opportunities resulting in a number of mergers and acquisitions that the company has undertaken successfully.

    The company’s product lie into 3 major segments termed as Pharmaceuticals more »

  • Billionaire Ken Fisher’s Healthcare Picks for Q3

    By Meena Krishnamsetty - July 21, 2013 | Tickers: GSK, JNJ, NVO, PFE, SNY

    In mid July, Fisher Asset Management, the asset management firm run by billionaire and Forbes columnist Ken Fisher, filed its 13F for the second quarter of 2013 with the SEC, disclosing many of its long equity positions as of the end of June. Insider Monkey tracks these filings in our database, using them to help us develop investment strategies (for example, we have found that the most popular small cap more »

  • Merck's Late-Stage Breakdown

    By Brandy Betz - July 18, 2013 | Tickers: AMGN, MRK, SNY

    The Food and Drug Administration cancelled an advisory meeting planned for Merck’s (NYSE: MRK) post-surgery drug sugammadex. It’s another blow to Merck as investors pay close attention to the beleaguered R&D department now turned over to Roger Perlmutter.

    Merck highlighted its top five late-stage projects during the full-year 2011 conference call last February: sugammadex, insomnia treatment suvorexant, HPV vaccine V503, osteoporosis drug odanacatib, and cholesterol drug Tredaptive more »

  • The Future of Sanofi's Insulin Empire

    By Brandy Betz - July 17, 2013 | Tickers: LLY, NVO, SNY

    Sanofi (NYSE: SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs Lyxumia and Lantus. Could these new drugs keep Sanofi near the top of the diabetes market heap?

    Lantus is Sanofi’s top-selling product, earning 5 billion euros (or about $6.5 billion at current exchange rates) in sales last year. But the drug more »

  • Has Multiple Myeloma Met its Match?

    By Ryan Guenette - July 16, 2013 | Tickers: CELG, JNJ, ONXX, SNY

    Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. This cancer can lead to abnormally high calcium levels, kidney failure, bone damage, and anemia-related fatigue. However, broad advancements are being made in treating the disease and Celgene (NASDAQ: CELG)(NASDAQ: CELG)(NASDAQ: CELG) is leading the charge.

    In a late stage study, its flagship blood-cancer drug Revlimid, assisted in extending the time in which more »

  • Why Investors Should Consider French Stocks

    By Bob Ciura - July 12, 2013 | Tickers: DANOY.PK, SNY, TOT

    Investors may write off France as a country of punishing taxes and economic calamity, but the truth is, there are some extremely profitable companies that call France home. It’s not hard to understand why. Despite the ongoing headwinds presented by the widespread European fiscal crisis, France remains the fifth-largest economy in the world by gross domestic product, according to the United Nations.

    And, recent evidence suggests that the French more »

  • Exploding Pipeline Makes BioMarin Attractive Takeover Target

    By colin simpson - July 11, 2013 | Tickers: BMRN, PFE, SNY

    The Orphan Drug pipeline of BioMarin Pharmaceutical (NASDAQ: BMRN) has been growing so rapidly that the company has been the object of many takeover rumors since 2006 when it was believed that Genzyme was eyeing them for a buyout. No buyout has occurred yet, but rumors persist and since 2006, shares have risen from $3.87 to over $70.  Further supporting this potential buyout is that Genzyme has been acquired more »

  • Could This Safe Play Help Eli Lilly?

    By Brandy Betz - July 11, 2013 | Tickers: BMY, LLY, GSK, NVO, SNY

    Note: This version has been amended to better reflect Victoza's dosage recommendations.

    At the American Diabetes Association meeting last month, Eli Lilly (NYSE: LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk (NYSE: NVO) and Bristol-Myers Squibb (NYSE: BMY).

    GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin more »

  • Don't Ignore These European Healthcare Stocks

    By Bob Ciura - June 28, 2013 | Tickers: AZN, NVS, SNY

    Healthcare stocks have rallied over the past couple years, and for good reason. Not only is the global economy gaining traction, but the demographic trends, particularly in the United States, are extremely favorable. It’s a cliché by now, but it’s still true, that America is an aging society. The Baby Boomer generation is rapidly approaching retirement, and in turn will require a great deal of healthcare services.

    As more »

  • Page 1 of 7